LUND, Sweden, May 30, 2023 /PRNewswire/ — Hansa Biopharma (“Hansa”), a pioneer in enzyme technology for rare immunological conditions, today announced the first patient has been dosed with imlifidase in the GOOD-IDES-02 trial, a global pivotal phase 3 trial in anti-glomerular basement…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.